PD‐L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study

BACKGROUND: PD‐1 inhibitors are routinely used for the treatment of advanced melanoma. This study sought to determine whether PD‐L1 expression on circulating tumor cells (CTCs) can serve as a predictive biomarker of clinical benefit and response to treatment with the PD‐1 inhibitor pembrolizumab. ME...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Khattak, Muhammad A., Reid, Anna, Freeman, James, Pereira, Michelle, McEvoy, Ashleigh, Lo, Johnny, Frank, Markus H., Meniawy, Tarek, Didan, Ali, Spencer, Isaac, Amanuel, Benhur, Millward, Michael, Ziman, Melanie, Gray, Elin
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Immuno‐Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066715/
https://ncbi.nlm.nih.gov/pubmed/32162809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0557
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados